ANTX fundamentals
An in-depth look to AN2 Therapeutics, Inc. operating, investing, and financing activities
ANTX free cash flow for Q3 24 is -12.01 M USD. For 2023, ANTX free cash flow was -53.29 M USD and operating cash flow was -53.29 M USD.
Q3 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−70.00 M
−35.00 M
0.00
35.00 M
70.00 M
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '21
Sep 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
TTM
Cash from operating activitiesYoY growth
−7.64 M
—
−11.60 M
−72.00%
−12.82 M
−33.65%
−11.80 M
−24.38%
−17.07 M
−123.46%
−17.59 M
−51.72%
−14.38 M
−12.16%
−12.01 M
−1.75%
−61.05 M
Cash from investing activitiesYoY growth
6.05 M
—
10.89 M
−22.11%
7.88 M
—
−62.46 M
−2,595.81%
420.00 K
−93.06%
26.29 M
+141.48%
16.46 M
+108.96%
18.72 M
—
61.89 M
Cash from financing activitiesYoY growth
0.00
—
199.00 K
−99.69%
19.05 M
+165.39%
66.07 M
—
−321.00 K
—
349.00 K
+75.38%
0.00
−100.00%
23.00 K
−99.97%
51.00 K
Free cash flowYoY growth
−7.64 M
—
−11.60 M
−72.00%
−12.82 M
−33.65%
−11.80 M
−24.38%
−17.07 M
−123.46%
−17.59 M
−51.72%
−14.38 M
−12.16%
−12.01 M
−1.75%
−61.05 M